

WO200153312 Comparison

ID AAM39781 standard; Protein; 772 AA.
XX
AC AAM39781;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2926.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58937.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2926; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.

XX

SQ Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MRLSSLLALLRPALPLILGLSLGCSLSLLRVSWIQEGEDPCVEAVGERGGPQNPDSSRAR 60
      |||
Db      1 mrlssllallrpalplilgslgcslsllrvswiqgedpcveavgerggpqnpsrar 60

Qy     61 LDQSDDEDFKPRIVPYRDPNPKPYKKVLRTRYIQTELGSRERLLVAVLTSRATLSTLAVAV 120
      |||
Db     61 ldqsdedfkdprivpyrddpnkpykkvlrtryiqtelgsrerllvavltsratlstlavav 120

Qy    121 NRTVAHHFPRLLYFTGQRGARAPAGMQVVSNGDERPAWLMSETLRHLHTHFGADYDWWFI 180
      |||
Db    121 nrtvahhfprllyftgqrgarapagmqvvshgderpawlmsetlrhlhthfgadydwwfi 180

Qy    181 MQDDTYVQAPRLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYLLSRSLLLRLR 240
      |||
Db    181 mqddtyvqaprlaalaghlsinqdlylgraeefigageqarychggfgyllsrslllrlr 240

Qy    241 PHLDGCRGDILSARPDEWLGRCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFL 300
      |||
Db    241 phldgcrgdilsarpdewlgrclidslgvgcvsqhggqqyrsfelaknrdpekegssaf 300

Qy    301 SAFAVHPVSEGTLMYRLHKRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGL 360
      |||
Db    301 safavhvpsegtlmyrlhkrfsalelerayseieqlqaqirnltvltpegeaglswpvgl 360

Qy    361 PAPFTPHSRFEVLGWDFYFTEQHTFSCADGAPKCPLQGASRADVGDALETALEQLNRRYQP 420
      |||
Db    361 papftphsrfevlgwdfyfteqhtfscadgapkcplqgasradvgdaletaleqlnrryqp 420

Qy    421 RLRFAQKQRLNNGYRRFDPARGMEYTLDLLLECVTQRGHRRALARRVSLLRPLSRVEILPM 480
      |||
Db    421 rlrfaqkqrllngyrrfdpargmeytldllecvtqrghrralarrvslrlplsrveilpm 480

Qy    481 PYVTEATRVQLVPLLVAAAAAPAFLEAFAANVLEPREHALLTLLLVIYGPREGGRGAPD 540
      |||
Db    481 pyvteatrqlvplllvaaaaapafleafaanvleprehalltlllviygpreggrgapd 540

Qy    541 PFLGVKAAAAELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTWTRPG 600
      |||
Db    541 pflgvkaaaaelerrypgtrlawlavraeapsqvrlmdvvskkhpvdtlffltwtrpg 600

Qy    601 PEVLNRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGDPSPSPGADPSRGAPI 660
      |||
Db    601 pevlnrcrmnaisgwqaffpvhfqefnpalspqrsppgppgagdpssppgadpsrgapi 660
```

QY 661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGHLHFRV 720
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsghlhfrav 720
 QY 721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQE QANST 772
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqe qanst 772

RESULT 2

AAB80269

ID AAB80269 standard; Protein; 772 AA.

XX

AC AAB80269;

XX

DT 24-APR-2001 (first entry)

XX

DE Human PRO339 protein.

XX

KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
 KW antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
 KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
 KW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
 KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
 KW ischaemia; inflammation.

XX

OS Homo sapiens.

XX

PN WO200104311-A1.

XX

PD 18-JAN-2001.

XX

PF 22-FEB-2000; 2000WO-US04414.

XX

PR 07-JUL-1999; 99US-0143048.

PR 26-JUL-1999; 99US-0145698.

PR 28-JUL-1999; 99US-0146222.

PR 08-SEP-1999; 99WO-US20594.

PR 13-SEP-1999; 99WO-US20944.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.

PR 29-NOV-1999; 99WO-US28214.

PR 30-NOV-1999; 99WO-US28313.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 20-DEC-1999; 99WO-US30999.

PR 05-JAN-2000; 99WO-US00219.

XX

PA (GETH) GENENTECH INC.

XX

PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;

XX

ID AAI58937 standard; cDNA; 2710 BP.
 AC AAI58937;
 DT 22-OCT-2001 (first entry)
 DE Human polynucleotide SEQ ID NO 1140.
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; ss.
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI; 2001-442253/47.
 DR P-PSDB; AAM39781.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX
 PS Claim 1; SEQ ID NO 1140; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;

Query Match 96.5%; Score 2692; DB 22; Length 2710;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2692; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 gggggttagttccgacaccttcacagttgaagagcaggcagaaggagttgtgaagacagg 157

Db 7 ggggggttagttccgacaccttcacagttgaagagcaggcagaaggagttgtgaagacagg 66
 Qy 158 acaatcttcttggggatgctggctcctggaagccagcgggcttgcctctgtctttggcctc 217
 Db 67 acaatcttcttggggatgctggctcctggaagccagcgggcttgcctctgtctttggcctc 126
 Qy 218 attgaccccagggttctctgggttaaaactgaaagcctactactggcctgggtgcccatcaat 277
 Db 127 attgaccccagggttctctgggttaaaactgaaagcctactactggcctgggtgcccatcaat 186
 Qy 278 ccattgatccttgaggctgtgcccctggggcaccacccctggcagggcctaccaccatgcg 337
 Db 187 ccattgatccttgaggctgtgcccctggggcaccacccctggcagggcctaccaccatgcg 246
 Qy 338 actgagctccctgttggtctctgctgcccagcggcttccctcatcttagggctgtctct 397
 Db 247 actgagctccctgttggtctctgctgcccagcggcttccctcatcttagggctgtctct 306
 Qy 398 ggggtgcagcctgagcctcctgcccgttctctggatccagggggaggagaagatccctg 457
 Db 307 ggggtgcagcctgagcctcctgcccgttctctggatccagggggaggagaagatccctg 366
 Qy 458 tgtcagggctgttaggggagcaggaggggccacagaatccagattcgagagctcggctaga 517
 Db 367 tgtcagggctgttaggggagcaggaggggccacagaatccagattcgagagctcggctaga 426
 Qy 518 ccaaagtgatgaagacttcaaaccgccgattgtccctactacagggaccccaacaagcc 577
 Db 427 ccaaagtgatgaagacttcaaaccgccgattgtccctactacagggaccccaacaagcc 486
 Qy 578 ctacaagaaggtgctcaggactcgggtacatccagacagagctgggctcccgtgagcgggt 637
 Db 487 ctacaagaaggtgctcaggactcgggtacatccagacagagctgggctcccgtgagcgggt 546
 Qy 638 gctgggtggtgtcctgacctcccgagctacactgtccactttggccgtggctgtgaaccg 697
 Db 547 gctgggtggtgtcctgacctcccgagctacactgtccactttggccgtggctgtgaaccg 606
 Qy 698 tacggtggcccatcacttccctcgggtactctacttcaactgggcagcggggggcccgggc 757
 Db 607 tacggtggcccatcacttccctcgggtactctacttcaactgggcagcggggggcccgggc 666
 Qy 758 tccagcagggatgcaggtggtgtctcatggggatgagcggcccgccctggctcatgtcaga 817
 Db 667 tccagcagggatgcaggtggtgtctcatggggatgagcggcccgccctggctcatgtcaga 726
 Qy 818 gacctgcgcacaccttcacacacactttggggccgactacgactgggttcttcatcatgca 877
 Db 727 gacctgcgcacaccttcacacacactttggggccgactacgactgggttcttcatcatgca 786
 Qy 878 ggatgacacatatgtgcaggcccccccgctggcagcccttgcctggccacctcagcatcaa 937
 Db 787 ggatgacacatatgtgcaggcccccccgctggcagcccttgcctggccacctcagcatcaa 846
 Qy 938 ccaagacctgtacttaggcggggcagaggagttcattgggcagggcagcagggcccggtg 997
 Db 847 ccaagacctgtacttaggcggggcagaggagttcattgggcagggcagcagggcccggtg 906
 Qy 998 ctgtcatgggggctttggctacctgttgcacggagttcctctgcttctgtcggccaca 1057
 Db 907 ctgtcatgggggctttggctacctgttgcacggagttcctctgcttctgtcggccaca 966
 Qy 1058 tctggatggctgcgaggagacattctcagtgcccgctcctgacgagtggttggacgctg 1117
 Db 967 tctggatggctgcgaggagacattctcagtgcccgctcctgacgagtggttggacgctg 1026

Qy 1118 cctcattgactctctgggctcggtgtgtctcacagcaccaggggcagcagtatcgctc 1177
 |||
 Db 1027 cctcattgactctctgggctcggtgtgtctcacagcaccaggggcagcagtatcgctc 1086
 |||
 Qy 1178 atttgaactggccaaaaatagggaacctgagaaggaaggagctcggtcttctcagtg 1237
 |||
 Db 1087 atttgaactggccaaaaatagggaacctgagaaggaaggagctcggtcttctcagtg 1146
 |||
 Qy 1238 cttcgccgtgcacctgtctccgaaggtacctcatgtaccggctccacaaacgcttcag 1297
 |||
 Db 1147 cttcgccgtgcacctgtctccgaaggtacctcatgtaccggctccacaaacgcttcag 1206
 |||
 Qy 1298 cgctctggagttggagcgggttacagtgaatagaacaactgcaggctcagatccggaa 1357
 |||
 Db 1207 cgctctggagttggagcgggttacagtgaatagaacaactgcaggctcagatccggaa 1266
 |||
 Qy 1358 cctgaccgtgctgacccccgaaggggagggcagggtgagctggcccgctgggctccctgc 1417
 |||
 Db 1267 cctgaccgtgctgacccccgaaggggagggcagggtgagctggcccgctgggctccctgc 1326
 |||
 Qy 1418 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1477
 |||
 Db 1327 tcctttcacaccacactctcgctttgaggtgctgggctgggactacttcacagagcagca 1386
 |||
 Qy 1478 caccttctcctgtgcagatggggctcccaagtgcactacaggggctagcaggcgga 1537
 |||
 Db 1387 caccttctcctgtgcagatggggctcccaagtgcactacaggggctagcaggcgga 1446
 |||
 Qy 1538 cgtgggtgatgcgttgagactgccctggagcagctcaatcggcgtatcagccccgct 1597
 |||
 Db 1447 cgtgggtgatgcgttgagactgccctggagcagctcaatcggcgtatcagccccgct 1506
 |||
 Qy 1598 gcgcttcagaaagcagcgactgctcaacggctatcggcgttcgaccagcagggggcat 1657
 |||
 Db 1507 gcgcttcagaaagcagcgactgctcaacggctatcggcgttcgaccagcagggggcat 1566
 |||
 Qy 1658 ggagtacacctggacctgctgttggaatgtgtgacacagcggtgggcaccggcgggccct 1717
 |||
 Db 1567 ggagtacacctggacctgctgttggaatgtgtgacacagcggtgggcaccggcgggccct 1626
 |||
 Qy 1718 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgccta 1777
 |||
 Db 1627 ggctcgcagggtcagcctgctgcggccactgagccgggtggaaatcctacctatgccta 1686
 |||
 Qy 1778 tgtaactgagggcaccagagtgagctgggtgctgcaactcctgggtgctgaagctgctgc 1837
 |||
 Db 1687 tgtaactgagggcaccagagtgagctgggtgctgcaactcctgggtgctgaagctgctgc 1746
 |||
 Qy 1838 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1897
 |||
 Db 1747 agccccggctttcctcgaggcgtttgcagccaatgtcctggagccacgagaacatgcatt 1806
 |||
 Qy 1898 gctcaccctgttgctggtctacgggccacgagaaggtggcgtggagctccagaccatt 1957
 |||
 Db 1807 gctcaccctgttgctggtctacgggccacgagaaggtggcgtggagctccagaccatt 1866
 |||
 Qy 1958 tcttgggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 2017
 |||
 Db 1867 tcttgggtgaaggctgcagcagcggagttagagcgacggtaccctgggacgaggctggc 1926
 |||
 Qy 2018 ctggctcgtgtgagcagagggcccttcccagggtgcgactcatggacgtggtctcgaa 2077
 |||
 Db 1927 ctggctcgtgtgagcagagggcccttcccagggtgcgactcatggacgtggtctcgaa 1986
 |||
 Qy 2078 gaagcaccctgtggacactctcttcttcttaccaccgtgtggacaaggcctgggcccga 2137

Db	1987	 gaagcaccctgtggacactctcttcttaccaccgtgtggacaaggcctgggcccga	2046
Qy	2138	agtcctcaaccgctgtgcgatgaatgccatctctggctggcaggccttctttccagtcga	2197
Db	2047	agtcctcaaccgctgtgcgatgaatgccatctctggctggcaggccttctttccagtcga	2106
Qy	2198	tttccaggagttcaatcctgcctgtcaccacagagatcacccccaggggccccgggggc	2257
Db	2107	tttccaggagttcaatcctgcctgtcaccacagagatcacccccaggggccccgggggc	2166
Qy	2258	tggccctgacccccctccctcctgggtgctgacccctcccggggggctcctataggggg	2317
Db	2167	tggccctgacccccctccctcctgggtgctgacccctcccggggggctcctataggggg	2226
Qy	2318	gagatttgaccggcaggcttctgcggagggtgcttctacaacgctgactacctggcggc	2377
Db	2227	gagatttgaccggcaggcttctgcggagggtgcttctacaacgctgactacctggcggc	2286
Qy	2378	ccgagcccggtggcagggtgaactggcaggccaggaagaggaggaagccctggaggggct	2437
Db	2287	ccgagcccggtggcagggtgaactggcaggccaggaagaggaggaagccctggaggggct	2346
Qy	2438	ggaggtgatggatgttttctccgggtctcagggtccacctctttcgggccgtagagcc	2497
Db	2347	ggaggtgatggatgttttctccgggtctcagggtccacctctttcgggccgtagagcc	2406
Qy	2498	agggctgggtgcagaagttctcctgcgagactgcagccacgggtcagtgaagaactcta	2557
Db	2407	agggctgggtgcagaagttctcctgcgagactgcagccacgggtcagtgaagaactcta	2466
Qy	2558	ccaccgctgccgcctcagcaacctggaggggctagggggccgtgccagctggctatggc	2617
Db	2467	ccaccgctgccgcctcagcaacctggaggggctagggggccgtgccagctggctatggc	2526
Qy	2618	tctctttgagcaggagcaggccaatagcacttagcccgctgggggcccctaacctcatta	2677
Db	2527	tctctttgagcaggagcaggccaatagcacttagcccgctgggggcccctaacctcatta	2586
Qy	2678	ccttttcctttgtctgcctcagccccaggaagggaaggcaagatgggtggacagatagaga	2737
Db	2587	ccttttcctttgtctgcctcagccccaggaagggaaggcaagatgggtggacagatagaga	2646
Qy	2738	attgttgctgtattttttaaatatgaaaatgttattaaacatgtcttctgcc	2789
Db	2647	attgttgctgtattttttaaatatgaaaatgttattaaacatgtcttctgcc	2698